IP Library Granted Patent US 9,376,406
Granted Patent B2
US 9,376,406 · App. 14/002,814 · Granted Jun 28, 2016

uPAR-uPA interaction inhibitors and methods for treating cancer

Inventor: Samy Meroueh (Carmel, IN)
Assignee: Indiana University Research and Technology Corporation
C07D261/20C07D413/04G01N33/5008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,376,406
App. No.
14/002,814
Granted
Jun 28, 2016
Kind
B2
Abstract

The invention described herein pertains to compounds, compositions and formulations comprising the compounds, and methods for use of the compounds, compositions and/or formulations in the treatment of diseases responsive to the inhibition of uPAR-uPA interactions, such as cancer.

Claims (23)

1. A method for imaging or diagnosing a population of pathogenic cells, the method comprising contacting the population with one or more compositions comprising a therapeutically effective amount of one or more compounds of the formula

or a pharmaceutically acceptable salt thereof, wherein

X is NH 2 , alkylamino, dialkylamino, or an optionally substituted nitrogen-containing heterocycle attached at nitrogen;

Y is optionally substituted aryl or optionally substituted heteroaryl; and

R A represents two substituents, each independently selected from the group consisting of hydrogen, halo, hydroxy, amino, thio, carboxylate, sulfinyl, sulfonyl, phosphinyl, phosphonyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heteroalkyl, heteroalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted; or R A is a fused aryl or heteroaryl, each of which is optionally substituted, and measuring a signal from the population.

2. The method of claim 1 , wherein the signal is a fluorescence signal.

3. The method of claim 1 , wherein the measuring step includes determining the red shift of the fluorescent signal.

4. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of the formula

or a pharmaceutically acceptable salt thereof, wherein R A is an optionally substituted fused aryl, X is an optionally substituted nitrogen-containing heterocycle attached at nitrogen and Y is an optionally substituted aryl, such that the compound is of the formula

or a pharmaceutically acceptable salt thereof, wherein

X 1 represents five substituents, each independently selected from the group consisting of hydrogen, halo, hydroxy, amino, thio, carboxylate, sulfinyl, sulfonyl, phosphinyl, phosphonyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heteroalkyl, heteroalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, each of which is optionally substituted;

Y 1 represents five substituents, each independently selected from the group consisting of hydrogen, halo, hydroxy, amino, thio, carboxylate, sulfinyl, sulfonyl, phosphinyl, phosphonyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heteroalkyl, heteroalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, each of which is optionally substituted; and

R A1 represents four substituents, each independently selected from the group consisting of hydrogen, halo, hydroxy, amino, thio, carboxylate, sulfinyl, sulfonyl, phosphinyl, phosphonyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heteroalkyl, heteroalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, each of which is optionally substituted.

5. The pharmaceutical composition of claim 4 , wherein, in the one or more compounds, or a pharmaceutically acceptable salt thereof, each X 1 is selected from hydrogen and alkyl; and each Y 1 is selected from hydrogen and carboxylate.

6. The pharmaceutical composition of claim 4 , wherein Y 1 in the one or more compounds, or a pharmaceutically acceptable salt thereof, is a single carboxylate.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula

or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of claim 4 , wherein the compound is a compound of the formula

or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition of claim 4 , wherein the compound is a compound of the formula

or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 4 , wherein the compound is a compound of the formula

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2014
From: MEROUEH, SAMY
To: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
Reel/Frame 033421/0778 →
CONFIRMATORY LICENSE Recorded Dec 13, 2013
From: INDIANA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031815/0197 →
Continuity (2)
Provisional Application 61448779 · Mar 3, 2011
Related Publication 20130338144A1 · Dec 19, 2013